Pharmacology Case Studies: Drug Interactions and Dosing
This paper presents four clinical pharmacology case studies examining real-world drug therapy challenges. The first case addresses warfarin management for deep vein thrombosis, including drug-drug interactions with celecoxib and aspirin, and the impact of CYP2C9 polymorphism on dosing. The second case analyzes atorvastatin's first-pass effect and bioavailability. The third case develops a treatment plan for a hyperlipidemia patient with multiple cardiovascular risk factors and a St. John's Wort interaction. The fourth case addresses hypertension management in an African American female patient who is non-adherent to metoprolol, recommending a switch to amlodipine per JNC 8 guidelines. Each scenario includes medication adjustments, prescriptions, patient education, and monitoring plans.
- Scenario 1: Warfarin Therapy for DVT Management: Warfarin dosing, drug interactions, and CYP2C9 impact
- Scenario 2: Atorvastatin Identification and Bioavailability: Atorvastatin first-pass effect and oral bioavailability
- Scenario 3: Hyperlipidemia Treatment and CAD Risk Factors: Statin therapy, lipid goals, and cardiovascular risk
- Scenario 4: Hypertension Management in an African American Patient: Amlodipine switch and JNC 8 blood pressure targets
- References: Cited sources across all four scenarios
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each case scenario follows a consistent clinical structure — problem identification, medication adjustments, monitoring, and patient education — making the reasoning easy to follow and evaluate.
- The paper integrates pharmacokinetic concepts (first-pass effect, CYP2C9 polymorphism, bioavailability) directly into clinical decision-making rather than treating them as abstract theory.
- Specific prescriptions with dosing, supply quantity, and refill information demonstrate applied clinical pharmacology knowledge beyond general recommendations.
Key academic technique demonstrated
The paper demonstrates applied clinical reasoning by connecting pharmacological mechanisms to therapeutic decisions. For example, rather than simply noting that celecoxib interacts with warfarin, the author explains the bleeding risk mechanism and proposes a safer alternative (acetaminophen), citing peer-reviewed sources to support each decision. This evidence-based approach ties pharmacodynamics and pharmacogenomics directly to patient-centered outcomes.
Structure breakdown
The paper is organized into four self-contained case scenarios, each covering a distinct clinical challenge. Within each scenario, subsections address the presenting problem, medication adjustments or therapy selection, patient education where applicable, goal parameters (INR range, lipid targets, blood pressure targets), and a monitoring plan. References are provided at the end of each scenario, then compiled into a full reference list. This parallel structure across all four cases makes the paper easy to navigate and compare.
Scenario 1: Warfarin Therapy for DVT Management
The patient is a 72-year-old male on warfarin (5 mg daily) for deep vein thrombosis (DVT) with a history of hypertension, hyperlipidemia, and osteoarthritis. He is also taking hydrochlorothiazide (HCTZ, 25 mg daily), celecoxib (200 mg daily), fluvastatin (40 mg daily), and Goody's Powder as needed for pain. There are potential drug-drug interactions between warfarin, celecoxib, and Goody's Powder, which contains aspirin. Additionally, the patient's warfarin dose may require adjustment due to his bleeding risk, influenced by his concurrent medications and a potential CYP2C9 polymorphism (Holail et al., 2022).
1. Warfarin: Continue warfarin but closely monitor INR levels (target INR for DVT: 2–3) (McRae et al., 2021).
Prescription: Warfarin 5 mg orally once daily, #30 (30-day supply), 0 refills. Monitor INR in 3–5 days.
2. Celecoxib: Discontinue celecoxib due to its interaction with warfarin, which increases the risk of bleeding.
Alternative: Acetaminophen 500 mg orally every 6 hours as needed for pain.
Prescription: Acetaminophen 500 mg, #60 (15-day supply), no refills. Maximum dose: 4 g/day.
3. Goody's Powder: Discontinue due to aspirin's interaction with warfarin, which increases the risk of bleeding.
Alternative: Acetaminophen as above for pain relief.
4. HCTZ and Fluvastatin: Continue both medications, as they do not have significant interactions with warfarin.
A CYP2C9 polymorphism can reduce warfarin metabolism, increasing its therapeutic effect and raising the risk of bleeding. In such cases, a lower starting dose of warfarin is recommended, and more frequent INR monitoring is essential. Genetic testing for CYP2C9 variants may be considered to guide therapy (Duarte & Cavallari, 2021).
INR levels should be checked every 3–5 days until stabilized within the therapeutic range (2–3). Liver function and signs of bleeding — such as bruising and dark stools — should also be monitored.
Duarte, J. D., & Cavallari, L. H. (2021). Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology, 18(9), 649–665.
Holail, J., Mobarak, R., Al-Ghamdi, B., Aljada, A., & Fakhoury, H. (2022). Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients. Drug Metabolism and Personalized Therapy, 37(4), 353–359.
McRae, H. L., Militello, L., & Refaai, M. A. (2021). Updates in anticoagulation therapy monitoring. Biomedicines, 9(3), 262.
Scenario 2: Atorvastatin Identification and Bioavailability
The pill with the imprint "P 80," round, yellow, and scored, is atorvastatin 80 mg, used for lowering cholesterol levels (Surma et al., 2023).
The first-pass effect refers to the metabolism of a drug by the liver following oral administration, which reduces the amount of active drug that reaches systemic circulation. For atorvastatin, the first-pass effect is significant and substantially reduces its bioavailability (Franco et al., 2020).
Bioavailability is the fraction of an administered drug that reaches systemic circulation in an active form. Drugs given intravenously have 100% bioavailability. When atorvastatin is given orally, its bioavailability is reduced due to the first-pass effect (Atkinson, 2022).
To bypass the first-pass effect, atorvastatin could theoretically be administered intravenously. However, atorvastatin is typically available only in oral form because it is designed to exert its primary effects after hepatic metabolism (Atkinson, 2022).
Atkinson, A. J., Jr. (2022). Drug absorption and bioavailability. In Atkinson's Principles of Clinical Pharmacology (pp. 43–59). Academic Press.
Franco, V., Gershkovich, P., Perucca, E., & Bialer, M. (2020). The interplay between liver first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations. Clinical Pharmacokinetics, 59, 1493–1500.
Always verify citation format against your institution’s current style guide requirements.